Plasma levels of soluble CD27: A simple marker to monitor immune activation during potent antiretroviral therapy in HIV-1-infected subjects

Clinical and Experimental Immunology

Volumn 127, Issue 3, 2002, Pages 486-494

  De Milito, A ^a,b   Aleman, S ^a   Marenzi, A ^b   Sonnerborg R ^a   Fuchs, D ^c   Zazzi, M ^d   Chiodi, F ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF INNSBRUCK   (Austria)

^d UNIVERSITY OF SIENA   (Italy)

Author keywords

HAART; HIV 1; Immune activation; Neopterin; Soluble CD27

Indexed keywords

ANTIRETROVIRUS AGENT; CD27 ANTIGEN; CD4 ANTIGEN; NEOPTERIN; VIRUS RNA;

ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; DRUG EFFECT; DRUG POTENCY; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE SYSTEM; LYMPHOCYTE COUNT; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; VIREMIA;

ANTIGENS, CD27; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIOLOGICAL MARKERS; CD4 LYMPHOCYTE COUNT; CROSS-SECTIONAL STUDIES; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV-1; HUMANS; LYMPHOCYTE ACTIVATION; NEOPTERIN; RNA, VIRAL; T-LYMPHOCYTES; VIRAL LOAD;

EID: 0036233519     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.2002.01786.x     Document Type: Article

References (49)

1. Control of lymphocyte function through CD27-CD70 interactions
2. Tissue distribution and biochemical and functional properties of Tp55 (CD27), a novel T cell differentiation antigen
3. S152 (CD27). A modulating disulfide-linked T cell activation antigen
4. A soluble form of the human T cell differentiation antigen CD27 is released after triggering of the TCR/CD3 complex
5. The CD27 membrane receptor, a lymphocytic-specific member of the nerve growth factor family, gives rise to a soluble form by protein processing that does not involve receptor endocytosis
6. The metalloproteinase inhibitor GI5402 inhibits endotoxin-induced soluble CD27 and CD16 release in healthy human
7. Role of CD27 in T cell immune response. Analysis by recombinant soluble CD27
8. Elevated soluble CD27 levels in serum of patients with systemic lupus erythematosus
9. Expression of the activation antigen CD27 in rheumatoid arthritis
10. Cerebrospinal fluid concentrations of soluble CD27 in HTLV-I associated myelopathy and multiple sclerosis
11. Expression and release of CD27 in human B-cell malignancies
12. Elevation of cerebrospinal fluid soluble CD27 levels in patients with meningeal localization of lymphoid malignancies
13. Aberrant expression of CD27 and soluble CD27 (sCD27) in HIV infection and in AIDS-associated lymphoma
14. Reduced ecto-5′-nucleotidase activity and enhanced OKT10 and HLA-DR expression on CD8 (T suppressor/cytotoxic) lymphocytes in the acquired immune deficiency syndrome: Evidence of CD8 cell immaturity
15. T-cell subset alterations in HIV-infected homosexual men: NIAID Multicenter AIDS cohort study
16. Three-color cytofluorometric analysis of CD8 cell subsets in HIV-1 infection
17. The Fas receptor in HIV infection: Expression on peripheral blood lymphocytes and role in the depletion of T cells
18. Activation of tumor necrosis factor-alpha system in HIV-1 infection: Association with markers of immune activation
19. Elevated serum levels of soluble Fas/APO-1 in human immunodeficiency virus-infected individuals
20. Elevated levels of soluble Fas and Fas ligand in cerebrospinal fluid of patients with AIDS dementia complex
21. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1
22. Cytokines, plasma immune activation markers, and clinically relevant surrogate markers in human immunodeficiency virus infection
23. Tumor necrosis factor (TNF) system levels in human immunodeficiency virus-infected patients during highly active antiretroviral therapy: Persistent TNF activation is associated with virologic and immunologic treatment failure
24. IL-10 in HIV infection: Increasing serum IL-10 levels with disease progression -down-regulatory effect of potent anti-retroviral therapy
25. High plasma levels of soluble Fas in HIV-1-infected subjects are not normalized during highly active antiretroviral therapy
26. Highly active antiretroviral therapy (HAART) and circulating markers of immune activation: Specific effect of HAART on neopterin
27. Changes in circulating levels of soluble cell adhesion molecules following highly active antiretroviral treatment of HIV-1-infected patients
28. + T cell homeostasis and function in advanced HIV disease
29. + T lymphocytes in a cohort of HIV type 1-infected patients treated with saquinavir, ritonavir, and two nucleoside analogs for 1 year, and association with plasma HIV type 1 RNA
30. Potent antiretrovi-ral therapy of primary human immunodeficiency virus type 1 (HIV-1) infection: Partial normalization of T lymphocyte subsets and limited reduction of HIV-1 DNA despite clearance of plasma viraemia
31. Expression of CD38 on CD8 T cells predicts maintenance of high viraemia in HAART-treated HIV-1-infected children. Highly active antiretroviral therapy
32. Long-term evaluation of T-cell subsets and T-cell function after HAART in advanced stage HIV-1 disease
33. Plasma levels of viro-immunological markers in HIV-infected and noninfected Ethio1pians: Correlation with cell surface activation markers
34. Clinical evaluation of an in-house reverse transcription-competitive PCR for quantitation of human immunodeficiency virus type 1 RNA in plasma
35. The role of neopterin as a monitor of cellular immune activation in transplantation, inflammatory, infectious and malignant diseases
36. Immune activation correlates better than HIV plasma viral load with CD4 T-cell decline during HIV infection
37. Highly active antiretroviral therapy during early HIV infection reverses T-cell activation and maturation abnormalities. Swiss HIV Cohort study
38. Immunological benefits of anti-retroviral therapy in very early stages of asymptomatic chronic HIV-1 infection
39. Maximum suppression of HIV replication leads to the restoration of HIV-specific responses in early HIV disease
40. Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy
41. Rate of HIV-1 RNA rebound upon stopping antiretroviral therapy
42. Pre-HAART HIV burden approximates post-HAART viral levels following interruption of therapy in patients with sustained viral suppression
43. Rapid activation of lymph nodes and mononuclear cell HIV expression upon interrupting highly active antiretroviral therapy in patients after prolonged viral suppression
44. CD27-CD70 interactions regulate B-cell activation by T cells
45. CD27, a member of the tumor necrosis factor receptor family, induces apoptosis and binds to Siva, a proapoptotic protein
46. + T cells
47. Loss of memory (CD27) B lymphocytes in HIV-1 infection
48. Serological markers of disease activity in tubercolosis and HIV infection
49. An evaluation of low-cost progression markers in HIV-1 seropositive Zambians